Entering text into the input field will update the search result below

Dosing underway in Moderna's study of COVID-19 vaccine in pediatric population

  • The first participants have been dosed in Moderna's (NASDAQ:MRNA) Phase 2/3 KidCOVE study, of mRNA-1273, in children ages 6 months to less than 12 years against COVID-19.
  • This Phase 2/3 two-part, dose-escalation, age de-escalation (Part 1) and observer-blind, placebo-controlled expansion study (Part 2) will evaluate the safety, tolerability, reactogenicity

Recommended For You

About MRNA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRNA--
Moderna, Inc.